Patents by Inventor Thomas A. McCauley

Thomas A. McCauley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9603908
    Abstract: The present invention provides, among other things, compositions, kits and methods for subcutaneous delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention provides methods for treating Hunter syndrome by subcutaneous administration of a replacement iduronate-2-sulfatase (I2S) protein. In some embodiments, the present invention provides a kit comprising an arrangement of components for subcutaneously administering iduronate-2-sulfatase (I2S) protein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 28, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Hongsheng Xie, Brian Felice, Thomas McCauley
  • Publication number: 20170042978
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Application
    Filed: February 4, 2016
    Publication date: February 16, 2017
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • Patent number: 9283181
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Grant
    Filed: June 25, 2011
    Date of Patent: March 15, 2016
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • Publication number: 20160030416
    Abstract: Methods of treating B2-bradykinin receptor mediated angioedema in a subject by administering a composition containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof. Oral formulations containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof for the treatment of B2-bradykinin receptor mediated angioedema. Use of a composition containing a 8-(heteroarylmethoxy)quinolone compound, a 8-(arylmethoxy)quinoline compound, or a salt, a stereoisomer, a hydrate, or a solvate thereof for the manufacture of a medicament for the treatment and/or prevention of a B2-bradykinin receptor mediated angioedema.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 4, 2016
    Inventors: Kevin Leach, Teresa Wright, Brian Felice, Richard Pfeifer, Pericles Calias, Thomas McCauley
  • Publication number: 20150328289
    Abstract: The present invention, provides a method of treating cognitive impairment of Hunter syndrome.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 19, 2015
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Ann BARBIER, Thomas MCCAULEY, Charles W. RICHARD, III
  • Publication number: 20150086526
    Abstract: The present invention provides, among other things, compositions, kits and methods for subcutaneous delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention provides methods for treating Hunter syndrome by subcutaneous administration of a replacement iduronate-2-sulfatase (I2S) protein. In some embodiments, the present invention provides a kit comprising an arrangement of components for subcutaneously administering iduronate-2-sulfatase (I2S) protein.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Inventors: Hongsheng Xie, Brian Felice, Thomas McCauley
  • Publication number: 20130295071
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease.
    Type: Application
    Filed: April 12, 2013
    Publication date: November 7, 2013
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Ken Manning, Gaozhong Zhu, Paul Campolieto, Zahra Shahrokh, Pericles Calias, Thomas McCauley
  • Publication number: 20120003202
    Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
    Type: Application
    Filed: June 25, 2011
    Publication date: January 5, 2012
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
  • Publication number: 20110318324
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease.
    Type: Application
    Filed: June 25, 2011
    Publication date: December 29, 2011
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Ken Manning, Gaozhong Zhu, Paul Campolieto, Zahra Shahrokh, Pericles Calias, Thomas McCauley
  • Publication number: 20090053138
    Abstract: Materials and methods are provided for producing and using aptamers as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and/or VEGF receptor or any combination thereof with affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: November 2, 2005
    Publication date: February 26, 2009
    Inventors: Jeffrey Preiss, Charles Wilson, Martin Stanton, John Diener, David Epstein, Dilara McCauley, Thomas McCauley
  • Publication number: 20070048248
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: February 14, 2006
    Publication date: March 1, 2007
    Inventors: Claude Benedict, David Epstein, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas McCauley, James Rottman, Charles Wilson
  • Publication number: 20060105980
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: December 22, 2005
    Publication date: May 18, 2006
    Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Keene, Jeffrey Kurz, Markus Kurz, Thomas McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna Zoltoski
  • Publication number: 20060030535
    Abstract: Materials and methods are provided to modulate, in a controlled manner, the pharmacokinetic and biodistribution properties of nucleic acid aptamers, and to enhance their safety and efficacy properties as therapeutic agents.
    Type: Application
    Filed: March 7, 2005
    Publication date: February 9, 2006
    Inventors: Judith Healy, Markus Kurz, Thomas McCauley, Kristin Thompson, Charles Wilson, Dorothy Margolskee
  • Publication number: 20060018871
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: February 14, 2005
    Publication date: January 26, 2006
    Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Keene, Jeffrey Kurz, Markus Kurz, Thomas McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna Zoltoski
  • Publication number: 20050159351
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: November 2, 2004
    Publication date: July 21, 2005
    Inventors: Dilara Grate, John Diener, Charles Wilson, Thomas McCauley
  • Publication number: 20050124565
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: June 21, 2004
    Publication date: June 9, 2005
    Inventors: John Diener, David Epstein, Alicia Ferguson, Dilara Grate, Anthony Keefe, Thomas McCauley, Jeffrey Preiss, Martin Stanton, Charles Wilson
  • Publication number: 20040253679
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: April 21, 2004
    Publication date: December 16, 2004
    Inventors: David Epstein, Dilara Grate, Martin Stanton, John L. Diener, Charles Wilson, Thomas McCauley, Errol DeSouza
  • Patent number: 6772060
    Abstract: An electronic engine control is provided that compensates the engine's power output capability based on the parasitic power load demands.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: August 3, 2004
    Assignee: Caterpillar Inc
    Inventors: Thomas A. McCauley, Marvin K. Palmer, Bryan A. Vogt
  • Publication number: 20040113573
    Abstract: A method of operating a fan control system associated with a radiator may include rotating a fan in a first direction at an operating speed to direct cool air toward the radiator for a first predetermined period of time. After expiration of the first predetermined period of time, rotation of the fan in the first direction may be decelerated. The method may also include accelerating the fan in a second direction opposite to the first direction and rotating the fan in the second direction at a predetermined speed for a second predetermined period of time. After expiration of the second predetermined period of time, rotation of the fan in the second direction may be decelerated, and the fan may then be accelerated in the first direction to the operating speed.
    Type: Application
    Filed: December 17, 2002
    Publication date: June 17, 2004
    Applicant: Caterpillar Inc.
    Inventors: Thomas A. McCauley, Bryan A. Vogt, James A. Morrison
  • Patent number: 6750623
    Abstract: A method of operating a fan control system associated with a radiator may include rotating a fan in a first direction at an operating speed to direct cool air toward the radiator for a first predetermined period of time. After expiration of the first predetermined period of time, rotation of the fan in the first direction may be decelerated. The method may also include accelerating the fan in a second direction opposite to the first direction and rotating the fan in the second direction at a predetermined speed for a second predetermined period of time. After expiration of the second predetermined period of time, rotation of the fan in the second direction may be decelerated, and the fan may then be accelerated in the first direction to the operating speed.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: June 15, 2004
    Assignee: Caterpillar Inc.
    Inventors: Thomas A. McCauley, Bryan A. Vogt, James A. Morrison